Cargando…

Atrial fibrillation: trends in prevalence and antithrombotic prescriptions in the community

INTRODUCTION: In the past decade, the atrial fibrillation (AF) landscape, including the treatment modalities, has drastically changed. This raises the question how AF prevalence and choices in antithrombotic therapy prescription have developed in the community over time. METHODS: Routine care data f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joosten, L. P. T., de Boer, A. R., van Eerde, E. J. B., van Doorn, S., Hoes, A. W., Bots, M. L., Rutten, F. H., Geersing, G. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bohn Stafleu van Loghum 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475006/ https://www.ncbi.nlm.nih.gov/pubmed/35230637 http://dx.doi.org/10.1007/s12471-022-01667-x

Ejemplares similares

Risk of cardiac and non-cardiac adverse events in community-dwelling older patients with atrial fibrillation: a prospective cohort study in the Netherlands
por: van Doorn, Sander, et al.
Publicado: (2018)

Antithrombotic management of patients with atrial fibrillation—Dutch anticoagulant initiatives anno 2020
por: Chu, G., et al.
Publicado: (2020)

Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis
por: Joosten, Linda P T, et al.
Publicado: (2023)

The effects of misclassification in routine healthcare databases on the accuracy of prognostic prediction models: a case study of the CHA2DS2-VASc score in atrial fibrillation
por: van Doorn, S., et al.
Publicado: (2017)

Time trends in antithrombotic therapy prescription patterns: Real-world monocentric study in hospitalized patients with atrial fibrillation
por: Abrignani, Maurizio Giuseppe, et al.
Publicado: (2022)

The Number of Concomitant Drugs and the Safety of Direct Oral Anticoagulants in Routine Care Patients with Atrial Fibrillation
por: van den Dries, Carline J., et al.
Publicado: (2020)

Integrated management of atrial fibrillation in primary care: results of the ALL-IN cluster randomized trial
por: van den Dries, Carline J, et al.
Publicado: (2020)

Safety of off‐label dose reduction of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
por: van den Dries, Carline J., et al.
Publicado: (2022)

Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial
por: Joosten, Linda P T, et al.
Publicado: (2019)

Integrated management of atrial fibrillation including tailoring of anticoagulation in primary care: study design of the ALL-IN cluster randomised trial
por: van den Dries, Carline J, et al.
Publicado: (2017)

Benefit of integrated care in patients with atrial fibrillation- a predictive heterogeneous treatment effect analysis of the ALL-IN trial
por: Trinks-Roerdink, E M, et al.
Publicado: (2023)

Antithrombotic therapy in atrial fibrillation: aspirin is rarely the right choice
por: Sabir, Ian N, et al.
Publicado: (2013)

Atrial fibrillation in patients with first-ever stroke: Incidence trends and antithrombotic therapy before the event
por: Jung, Yo Han, et al.
Publicado: (2018)

The use of antithrombotics in patients presenting with stroke and atrial fibrillation
por: Burgess, Carl, et al.
Publicado: (2007)

Update on Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation
por: Abcede, Hermelinda G., et al.
Publicado: (2010)

The sunset of triple antithrombotic therapy for atrial fibrillation patients
por: Capranzano, Piera
Publicado: (2019)

Comorbidities and Antithrombotic Treatment Pattern in Patients With Atrial Fibrillation
por: Bang, Oh Young, et al.
Publicado: (2022)

Sex- and age specific association of new-onset atrial fibrillation with in-hospital mortality in hospitalised COVID-19 patients
por: Offerhaus, Joost A., et al.
Publicado: (2022)

Managing the Increasing Burden of Atrial Fibrillation through Integrated Care in Primary Care: A Cost-Effectiveness Analysis
por: van den Dries, Carline J., et al.
Publicado: (2023)

Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome
por: Bor, Wilbert, et al.
Publicado: (2020)

Integrated care in patients with atrial fibrillation- a predictive heterogeneous treatment effect analysis of the ALL-IN trial
por: Trinks-Roerdink, Emmy M., et al.
Publicado: (2023)

Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF
por: Kozieł, Monika, et al.
Publicado: (2021)

Incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes
por: Groenewegen, Amy, et al.
Publicado: (2021)

Antithrombotic therapy in coronary artery disease patients with atrial fibrillation
por: Wei, Lili, et al.
Publicado: (2020)

Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease
por: Moustafa, Abdelmoniem, et al.
Publicado: (2019)

Post‐Intracranial Hemorrhage Antithrombotic Therapy in Patients With Atrial Fibrillation
por: Lin, Shin‐Yi, et al.
Publicado: (2022)

Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation
por: Camm, A John, et al.
Publicado: (2017)

Optimal long-term antithrombotic management of atrial fibrillation: life cycle management
por: Pisters, R., et al.
Publicado: (2018)

Real world time trends in antithrombotic treatment for newly diagnosed atrial fibrillation in China: reports from the GLORIA-AF Phase III registry: Trends in antithrombotic therapy use in China
por: Liu, Xiaoxia, et al.
Publicado: (2023)

Sex-specific and age-specific incidence of ischaemic heart disease, atrial fibrillation and heart failure in community patients with chronic obstructive pulmonary disease
por: Groenewegen, Amy, et al.
Publicado: (2022)

Prevalence of Valvular and Non-valvular Atrial Fibrillation and the Application of Antithrombotic Treatment in a Tertiary Care Hospital
por: Dhungana, Sahadeb Prasad, et al.
Publicado: (2020)

The Rate of Clinical Outcomes in Atrial Fibrillation according to Antithrombotic Strategy: The COOL-AF Registry
por: Krittayaphong, Rungroj, et al.
Publicado: (2022)

Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillation
por: Chu, Gordon, et al.
Publicado: (2020)

Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach
por: Suárez Fernández, Carmen, et al.
Publicado: (2015)

Impact of Antithrombotic Therapy in Atrial Fibrillation on the Presentation of Coronary Artery Disease
por: Chan, Pak Hei, et al.
Publicado: (2015)

Antithrombotic Strategy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
por: Kwak, Soongu, et al.
Publicado: (2019)

Antithrombotic treatment in atrial fibrillation patients needing percutaneous coronary intervention
por: Huisman, M. V.
Publicado: (2021)

Antioxidant Properties of Oral Antithrombotic Therapies in Atherosclerotic Disease and Atrial Fibrillation
por: Falco, Luigi, et al.
Publicado: (2023)

Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention: A nationwide Korean population-based study
por: Park, Jiesuck, et al.
Publicado: (2019)

European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care
por: Hobbs, FD Richard, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1vdl74sdi3lqokfb0699for6k9